Somatic alterations of the SMAD-2 gene in human colorectal cancers. by Takagi, Y. et al.
Britsh Journal of Cancer(1998) 78(9). 1152-1155
1998 Cancer Reearch CampaKgn
Somatic alterations of the SMIAD-2 gene in human
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'Department of Surgery 11 and 2Departmeent of Laboratory Medicine. Gifu University School of Medicine, Tsukasa-machi, Gifu 500-8705. Japan
Summary The SMAD-2gene, which is located at 18q21, has been identified as a candidate tumour-suppressor gene from work on colorectal
cancers. The aim of the present study was to determine the clinical alterations and the significance of its mutations in a series of colorectal
cancers previously examined for SMAD-4/DPC-4 gene. Mutation analyses of the SMAD-2 gene were carried out on cDNA samples from 36
primary colorectal cancer specimens using a combination of the polymerase chain reaction (PCR), single-strand conformation polymorphism
(SSCP) and DNA sequencing. Only one missense mutation (2.8%), producing an amino acid substitution in the highly conserved region, and
two homozygous deletions (5.5%) of the total coding region of the SMAD-2 gene were detected in the 36 cancers. The SMAD-2 gene may
play a role as a candidate tumour-suppressor gene in a small fraction of colorectal cancers. However, allelic loss at 18q21 is very often seen
in this type of tumour. Even in combination with changes in SMAD-4, the observed frequency was not sufficient to account for all 18q21
deletions in colorectal cancers. Thus, another tumour-suppressor gene, such as DCC, discovered as the first tumour-suppressor candidate in
the region may also exist in this chromosome region.
Keywords: SMAD-Z colorectal cancer, SMAD-4; 18q21
Tumour-suppressor genes are charactenrzed by alterations that
inactivate both alleles in cancers (Knudson et al. 1985). this often
being accomplished by intragenic mutations in one allele accom-
panied by loss ofa chromosomal region containing the other allele
termed loss of heterozygosity (LOH). LOH at 18q21 has been
reported to be frequent in various types ofhuman tumours such as
pancreatic and colon cancers (Vogelstein et al. 1989: Cliby et al.
1993: Brewster et al. 1994: Shibagaki et al. 1994: Hahn et al.
1995: Vogelstein et al. 1988). Recently. we showed that the
SMAD-4 gene. which was initially isolated from 18q21 as a candi-
date tumour-suppressor gene for pancreatic cancers (Hahn et al.
1996). is somatically mutated in a proportion ofcolorectal cancers
in vivo (Takagi et al. 1996). However. the observed frequency of
SMAD-4 mutations was significantly lower than expected from the
numbers of 18q21 deletions in colorectal cancers. indicating that
another tumour-suppressor gene might be present in this chromo-
some region. For instance. the DCC was the first candidate tumour
suppressor in the region. although data on DCC mutations in the
same set of tumour samples presented here are not available at
present because of its length and complexity.
More recently. a novel gene. termed SMAD-2. has been isolated
and revealed to be closely related to the SMAD-4 gene (Riggins et
al. 1996: Eppert et al. 1996). Of interest. it w-as mapped to the
18q21 region within a short distance. 3 Mb. from the SMAD4
gene. These observations led us to examine whether the SMAD-2
gene might also be mutated in the same set of colorectal cancers
already examined for SMAD-4 gene changes.
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We herein report our results for SMAD-2 mutations from 36
colorectal cancer specimens. taken at surgery from Japanese
patients. together with comparatis e data for the molecular status of
the SMAD4 gene. Somatic in vivo SMAD-2 mutations were
found. although at very low frequency. providing further evidence
that alterations of MAD-related genes at 18q2 1 are indeed
involved in the pathogenesis ofcolon cancers.
MATERIALS AND METHODS
Patients and tissue samples
Samples of tumours and matched control normal colorectal tissue
located far from the tumour site were collected at surgery from 36
patients diagnosed histologically as havsing colorectal cancers. All
tissues were quickly frozen in liquid nitrogen and stored at-80°C
until analysed.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
Two micrograms of total RNA. isolated and purified by standard
procedures. were reverse transcribed usin- 0.3 ,g of random
primers. 20 U of RNase inhibitor. 10 mmol 1-' ofdeoxynucleoside
triphosphates and 20 U of reverse transcriptase (Takara
Biomedicals. Kyoto. Japan) using, the manufacturer's suggested
reaction conditions. The polymerase chain reaction (PCR) was
performed in 25-pg reaction mixtures containing, the followinga:
1 pi of the complementarv DNA mix. 2.5 jl of 10 x PCR buffer
(50 mmol 1-'. lOmmol 1-' Tris-HCl. pH 8.3. and 1.5 mmol 1-1
magnesium chloride). 4.0 mmol 1-1 deoxynucleoside triphos-
phates. 2 mCi [a- 'P] dCTP (2000 Ci mmol-'. Amersham. UK).
This w-ork sA-as supported in part by a Grant-in-Aid for the Research Fund for
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Figure 2 Sequence analysis of the SMAD-2 gene in colorectal cancer
specimens and the corresponding normal colorectal samples of case 31. A
missense mutation (CAT to CGT) at codon 441 is apparent in colorectal
cancer tissue of case 31. Note that these mutations are not present in the
patents' normal colorectal samples, indicating that they occurred as in vivo
somatic mutations in the tumours
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Figure 1 PCR/SSCP analysis of the SMAD-2 gene in coorectal cancer
specimens. (A) Schematc diagram of the strategy for PCR/SSCP analysis
of SMAD-2 cDNAs as well as that of SMAD-2 mRNA are shown. Open
box, coding region: stippled boxes, 5' and 3' untranslated regions.
(B) Representative results of PCR/SSCP analysis using S5 and AS5 primers.
Abnormal mobility shifts are apparent in case 31
1.25 U Taq polymerase (Takara). and 0.5 m-st ofeach PCR primer.
Primers for SMAD-2 were designed to amplify the gene in five
overlapping segments (Figure lA). The primer pairs used were as
follows:
S I (sense). 5'-AGC GAA TTC TGG C(1T1 GCT GCC TTl-
GGT AAG A and AS I (antisense). 5'-AGC GAG CTC CGT
ATT TGG TGT ACT CAG TCC C (281 bp): S2 (sense). 5'-
AGC GAA TTC ACC ATA CCA AGC ACT TGC TCF G and
AS2 (antisense). 5'-AGC GAG CTC TCC AGA GGC GGA
AGT TCT GTT A (337 bp): S3 (sense). 5'-AGC GAA TTC
GCC AGT TAC TTA CTC AGA ACC T and AS3 (antisense).
5'-AGC GAG CTC GCA CTC CTC TTC CTA TAT GCC T
(228 bp): S4 (sense). 5'-AGC GAA TTC CCG AAA TGC
CAC GGT AGA AAT G and AS4 (antisense). 5'-AGC GAG
CTC CTG ATA GAC GGC TTC AAA ACC C (272 bp): S5
(sense). 5'-AGC GAA TTC GCT CT-l CTG GCT CAG TCT
GTT A and AS5 (antisense). 5'-AGC GAG CTC CAT GGG
ACT TGA TTFG GTG AAG C (264 bp).
The reactions were programmed for thermal cvcling as follo, s
(PCR thermal cycler MP: Takara Biomedicals): the initial dena-
turing step w as for min at 943C. followed by 35 cycles of30 s at
94CC for denaturation. 30 s at 55°C for annealing and min at
72'C for extension. The final extension for all PCR reactions was
at 72C for 10 min.
Detection of single-strand conformation
polymorphism (SSCP)
The SSCP analysis was performed essentially as described by
Orita et al (1989). Aliquots (1 pl) of radiolabelled PCR products
were diluted with 25 jl of loading buffer (95% formamide. 20 nmi
EDTA. 0.05% bromophenol blue. 0.05%7 xylene cyanol). heat
denatured for 10 min. and chilled on ice. Three microlitres ofeach
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Figure 3 Schematic diagram of the SMAD-2 protein as well as locations of
the predicted amino acid alterations resulting from the identified mutations in
case 31. The amino acid sequence of SMAD-2from amino acids 431 to 454
of the MH2 domain are aligned with the corresponding regions in SMAD-1
and SMAD-4. Conserved sequences are highlighted (black box)
mixture wvas applied to 6%c non-denaturing polyacrvlamide gels
(acrylamide and N-N'-bisacrvlamide. 28:2. and 10%7c glvcerol) and
electrophoreticaly separated at 30 W constant power for 4 h. The
resultingy bands were visualized after autoradioggraphy with Kodak
XAR films for day. Abnormal samples were repeatedly tested in
independent PCR reactions and with separate gel loadings to
ensure reproducibility.
Sequence analysis for mutations
After digestion with EcoRI-SacI. the RT-PCR products of
colorectal cancer specimens shosing abnormal PCR/SSCP
pattems were resolved on 0.8% agarose gels and isolated using
Geneclean II (Bio 101. La Jolla. CA. USA). After cloning into
EcoRI-SacI sites of pBluescript SKII(-) (Stratagene. La Jolla.
CA. USA). plasmid DNAs prepared from pooled clones were
sequenced by the dideoxv chain termination method (Suzuki et al.
1992). Identified mutations were confirmed by separate
cDNA/PCR amplification and subsequent sequencing. RT-PCR
products of the corresponding normal colorectal RNAs vk-ere also
subjected to PCR/SSCP and sequencing analyses.
Clinicopathological data
Data including gender. age. stage of disease and histopathological
findings were available from the clinical and pathological records.
A clinicopathological staging derised from the oniginal Dukes'
classification was applied. Stage A tumours were defined as being
confined to the bowel wall. stage B tumours as extending into the
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pericolic/perirectal fat or beyond the serosa or both, stage C
tumours were either stage A or stage B with lymph node metas-
tases, and stage D tumours were those with distant metastases. The
differentiation grade was assessed.
RESULTS
The present examination of 36 colorectal cancer specimens using
the RT-PCR and analysis of single-strand conformation polymor-
phisms (RT-PCR/SSCP), yielded positive data for three cases. In
case 31, a distinct mobility shift was present in the colorectal cancer
specimen but not in the corresponding normal tissue, indicating a
somatic nature for the change. Both mutant and wild-type alleles
were expressed at similar RNA levels indicating retention of
heterozygosity (Figure 1B). In two colorectal specimens, cases 4
and 5, the total coding region ofboth alleles were absent, suggesting
possible homozygous deletions at 18q21 (data not shown).
Sequence analysis ofthe normal and colorectal cancer specimens
for case 31 showed the presence of a somatic missense mutation. A
change ofCAT to CGT in a highly conserved residue at codon 441
(Figure 2) within the MAD homology 2 (MH2) region of the
SMAD-2 protein was found, leading to an amino acid substitution
(change from histidine to arginine) (Figure 3).
Correlations between mutations and clinicopathological status
are shown in Table 1. The SMAD-2 mutation was present in an
early stage lesion, whereas the SMAD-4 mutations were primarily
in cases with liver and lymph node metastasis.
DISCUSSION
The vast majority of human epithelial and lymphoid malignant
tumour cell lines demonstrate escape from transforming growth
factor (TGF-P)-mediated growth control, which may represent
an important step in tumour progression (Fynan et al, 1993).
Recently, several novel human genes related to the Drosophila
gene called MAD, thought to transduce signals from TGF-, family
members, have been identified, with SMAD-2 being one of these
(Sekelsky et al, 1995; Graff et al, 1996; Hoodless et al, 1996;
Savage et al, 1996). We here identified one somatic mutation in the
highly conserved MH2 domain of the SMAD-2 gene in 36
colorectal cancer specimens. This alteration would be expected to
disrupt regulation of phosphorylation by the TGF-f signalling
pathway.
Previously, we reported detection of alterations of the SMAD-4
gene in a subset of the present series of colorectal cancers
(Takagi et al, 1996). In total, one SMAD-2 and five SMAD-4 muta-
tions and two homozygous deletions of the two genes were
observed (Table 1). The SMAD-2 mutation was present in an early
stage lesion, whereas the SMAD-4 mutations were primarily
in cases with liver and lymph node metastasis (P = 0.0026 and
P = 0.0023 respectively by the chi-squared test). Further studies
should be carried out to clarify the relation between mutations of
MAD-related genes and disease stage ofcolorectal cancers.
The discrepancy between the frequencies of SMAD-2 and
SMAD-4 mutations and that ofallelic loss at 18q2 I still remains to
be explained. Using RNAs from microdissected tumour speci-
mens, RT-PCR/SSCP analysis might yield higher mutation
frequencies ofMAD-related genes. However, another possibility is
that there is yet another putative tumour-suppressor gene at 18q21
playing a role in colorectal carcinogenesis. The other alternative is
that MAD-related genes might be inactivated by other molecular
Table 1 Correlation between somatic mutations in the MAD-related genes
and patient and tumour characteristics
Clinical feature No. of cases SMAD-2 mutation SMAD-4 mutationa
Age
<66 18 0 3
.66 18 1 2
Sex
Men 18 1 3
Women 18 0 2
Histology
Well 19 1 0
Moderately 13 0 4
Poorly 3 0 0
Mucinous 1 0 1
Dukes' stage
A 4 0 0
B 15 1 0
C 10 0 2
Db 7 0 3
aPreviously published in Takagi et al (1996). bAll cases with liver metastasis.
mechanisms such as aberrant hypermethylation leading to tran-
scriptional repression (Baylin et al, 1991), although it might not
play a major role.
In conclusion, together with our previous demonstration of
SMAD-4 alterations in colorectal cancers, the present findings
indicate that the biological and biochemical functions ofthe MAD-
related genes, SMAD-2 and SMAD-4, warrant further investigation
to gain insights into the molecular pathogenesis of neoplasia.
Future studies may lead to identification of another, yet unidenti-
fied, tumour-suppressor gene(s) linked with the reported frequent
l8q21 deletions in colorectal cancers.
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